Abstract
Purpose
It remains unclear if use of amiodarone pre-cardiac transplantation impacts early post-transplant survival.
Methods
We selected all patients undergoing heart transplant from 2004 to 2006 with available information using the United Network for Organ Sharing database (n = 4057). Multivariable Cox models compared the risk of death within 30 days post-transplant in patients who were taking amiodarone at the time of transplant listing (n = 1227) to those who were not (n = 2830).
Results
Mean age was 52 (± 12) years, and 23% were women. Patients who died within 30 days (n = 168) were older; had higher panel reactive antibody levels, higher bilirubin levels, and higher prevalence of prior cardiac surgery; were often at status 1B; and had higher use of amiodarone at listing compared to those who survived (5.3% versus 3.6%; p = 0.02). Cause of death was unknown in 49% and was reported as graft failure in 43% of cases. In multivariable Cox models, patients on amiodarone at the time of listing had 1.56-fold higher risk of post-transplant death within 30 days (95% confidence intervals 1.08–2.27) compared to patients who were not on amiodarone at listing (C-statistic 0.70).
Conclusion
In conclusion, patients who reported taking amiodarone at the time of listing for transplant had a higher risk of death within 30 days post-transplant.
Similar content being viewed by others
References
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.
Stevenson LW. Crisis awaiting heart transplantation: sinking the lifeboat. JAMA Intern Med. 2015;175(8):1406–9.
Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1056–66.
Durand CM, Bowring MG, Thomas AG, et al. The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study. Ann Intern Med. 2018;168(10):702–11.
Mehra MR, Jarcho JA, Cherikh W, et al. The drug-intoxication epidemic and solid-organ transplantation. N Engl J Med. 2018;378(20):1943–5.
Stevenson LW. The urgent priority for transplantation is to trim the waiting list. J Heart Lung Transplant. 2013;32(9):861–7.
Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33(10):996–1008.
Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report--2013; focus theme: age. J Heart Lung Transplant. 2013;32(10):951–64.
Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplantation report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34(10):1244–54.
Chen JW, Chen YS, Chi NH, et al. Risk factors and prognosis of patients with primary graft failure after heart transplantation: an Asian center experience. Transplant Proc. 2014;46(3):914–9.
Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014;33(4):327–40.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.
Giardina EG, Schneider M, Barr ML. Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation. J Am Coll Cardiol. 1990;16(4):943–7.
Blomberg PJ, Feingold AD, Denofrio D, et al. Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone. Am J Cardiol. 2004;93(3):379–81.
Chin C, Feindel C, Cheng D. Duration of preoperative amiodarone treatment may be associated with postoperative hospital mortality in patients undergoing heart transplantation. J Cardiothorac Vasc Anesth. 1999;13(5):562–6.
Yerebakan H, Naka Y, Sorabella R, et al. Amiodarone treatment prior to heart transplantation is associated with acute graft dysfunction and early mortality: a propensity-matched comparison. J Heart Lung Transplant. 2014;33:S105.
Chelimsky-Fallick C, Middlekauff HR, Stevenson WG, et al. Amiodarone therapy does not compromise subsequent heart transplantation. J Am Coll Cardiol. 1992;20(7):1556–61.
Macdonald P, Hackworthy R, Keogh A, et al. The effect of chronic amiodarone therapy before transplantation on early cardiac allograft function. J Heart Lung Transplant. 1991;10(5 Pt 1):743–8 discussion 8–9.
Sanchez-Lazaro IJ, Almenar L, Martinez-Dolz L, et al. Does amiodarone influence early mortality in heart transplantation? Transplant Proc. 2006;38(8):2537–8.
Organ Procurement and Transplant Network Policies. 2020. https://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf. Accessed 30 Sept 2020.
Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187–220.
Sharing UNOO. Explanation of CPRA for professionals. https://unos.org/wp-content/uploads/unos/CPRA_Professionals.pdf. Accessed 3 Oct 2020.
Dronavalli VB, Rogers CA, Banner NR. Primary cardiac allograft dysfunction-validation of a clinical definition. Transplantation. 2015;99(9):1919–25.
Wright M, Takeda K, Mauro C, et al. Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. J Heart Lung Transplant. 2017;36(11):1226–33.
Hoemann B, Takayama H, Jennings DL, et al. Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. Clin Transpl. 2020;34(2):e13779.
Russo MJ, Iribarne A, Hong KN, et al. Factors associated with primary graft failure after heart transplantation. Transplantation. 2010;90(4):444–50.
Segovia J, Cosio MD, Barcelo JM, et al. RADIAL: a novel primary graft failure risk score in heart transplantation. J Heart Lung Transplant. 2011;30(6):644–51.
Cooper LB, Mentz RJ, Edwards LB, et al. Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. J Heart Lung Transplant. 2017;36(2):202–10.
Murphy C, Feifel E, Jennings P, Gstraunthaler G, Wilmes A. A protocol for one-step differentiation of human induced pluripotent stem cells into mature podocytes. Methods Mol Biol. 2019;1994:93–9.
Lushaj EB, Dhingra R, Chindhy S, et al. To use or not to use? Amiodarone before heart transplantation. Surgery. 2017;161(5):1273–8.
Rivinius R, Helmschrott M, Ruhparwar A, et al. Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. Drug Des Dev Ther. 2016;10:677–86.
Jennings DL, Baker WL. Pre-cardiac transplant amiodarone use is not associated with postoperative mortality: An updated meta-analysis. Int J Cardiol. 2017;236:345–7.
Jennings DL, Martinez B, Montalvo S, Lanfear DE. Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. Heart Fail Rev. 2015;20(5):573–8.
Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007;356(9):935–41.
Bertolet BD, Eagle DA, Conti JB, Mills RM, Belardinelli L. Bradycardia after heart transplantation: reversal with theophylline. J Am Coll Cardiol. 1996;28(2):396–9.
Goldstein DR, Coffey CS, Benza RL, Nanda NC, Bourge RC. Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation. Am J Transplant. 2003;3(4):484–91.
Montero JA, Anguita M, Concha M, et al. Pacing requirements after orthotopic heart transplantation: incidence and related factors. J Heart Lung Transplant. 1992;11(4 Pt 1):799–802.
Woo GW, Schofield RS, Pauly DF, et al. Incidence, predictors, and outcomes of cardiac pacing after cardiac transplantation: an 11-year retrospective analysis. Transplantation. 2008;85(8):1216–8.
Zieroth S, Ross H, Rao V, et al. Permanent pacing after cardiac transplantation in the era of extended donors. J Heart Lung Transplant. 2006;25(9):1142–7.
Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736–9.
Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother. 1993;27(5):569–71.
Nicolau DP, Uber WE, Crumbley AJ 3rd, Strange C. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant. 1992;11(3 Pt 1):564–8.
Preuner JG, Lehle K, Keyser A, et al. Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients. Transplant Proc. 1998;30(8):3943–4.
Schwarz ER, Czer LS, Simsir SA, Kass RM, Trento A. Amiodarone-induced QT prolongation in a newly transplanted heart associated with recurrent ventricular fibrillation. Cardiovasc J Afr. 2010;21(2):109–12.
Kisters K, Cziborra M, Funke C, Brylak S, Hausberg M. Amiodarone-tacrolimus interaction in kidney transplantation. Clin Nephrol. 2008;70(6):563.
Acknowledgments
This work was supported in part by the Health Resources and Services Administration contract 234-2005-370011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
Author information
Authors and Affiliations
Contributions
Salman S. Allana, MD: Participated in research design and drafting of the paper.
Furqan A. Rajput, MD, MS: Participated in drafting and critical revision of the paper.
Jason W. Smith, MD: Participated in critical revision with intellectual content.
Lucian Lozonschi, MD: Participated in research design and critical revision of the paper.
Jinn-ing Liou, MS: Participated in data analysis and interpretation.
Maryl Johnson, MD: Participated in critical revision of the paper.
Takushi Kohmoto, MD, PhD: Participated in critical revision of the paper.
Ravi Dhingra, MD, MPH: Participated in research design, data analysis, data interpretation, and drafting of the paper.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval and Informed Consent
Due to the retrospective nature of our study using de-identified data from the UNOS registry, the protocol was exempt from the University of Wisconsin-Madison Institutional Review Board. Informed consent was also deemed not necessary for this study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Allana, S.S., Rajput, F.A., Smith, J.W. et al. Amiodarone Use Prior to Cardiac Transplant Impacts Early Post-Transplant Survival. Cardiovasc Drugs Ther 35, 33–40 (2021). https://doi.org/10.1007/s10557-020-07092-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-020-07092-9